MEMORIAL HEALTH SYSTEM

GLP-1 Weight Loss Medications: Expert Perspectives on Efficacy, Candidates, and Long-Term Weight Maintenance

- Dr. Christopher Jones of Memorial Health System reports Semaglutide yields 10–12% weight loss, Tirzepatide 15–20%, and the investigational Retatrutide 20–25% after more than a year of use. - Gallup data shows GLP-1 usage nearly tripled from 6% in 2024 to 15% in 2026, underscoring sharply rising adoption. - Registered dietitian Sarah Smith warns that weight often returns after stopping GLP-1s and emphasizes the need for consistent eating and exercise habits alongside pharmacotherapy. - Ideal candidates include patients with diabetes or a BMI over 30; common side effects are gastrointestinal, including nausea, acid reflux, and vomiting.